Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination tria
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
(Date:10/22/2014)... 21, 2014   BioNano Genomics , the ... research centers to purchase an Irys™ System . ... Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) and ... obtaining a comprehensive view of a genome was ... does not deliver the scalability or reliability to ...
(Date:10/22/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a ... reported financial results for the second fiscal quarter ended ... , Revenues of $53.9 million, up 18% over last ... up 33% over last year,s comparable quarter. ... Reference Laboratories (AVRL) of $3.5 million, up 50% over ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
(Date:10/22/2014)... Viejo, CA (PRWEB) October 22, 2014 ... Jay Cormier, Sr. Vice President of Sales, will be ... the upcoming Meetings Technology Expo on October 28, at ... also be hosting a booth as well as a ... how Lintelus Meeting can create a more engaging event ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... lead to increased blood pressure, according to a new study. ... blood pressure for young adult women or for teenagers, according ... lightly or moderately, their risk of high blood pressure was ... studies in older adult men and women," said lead researcher ...
(Date:10/22/2014)... taken by Firestone officials at the company,s rubber ... spread of the disease there and could prove effective ... provides health services to about 80,000 employees, retirees, their ... Between Aug. 1 and Sept. 23, there were 71 ... That incidence rate of 0.09 percent was much lower ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... CHINA (October 13, 2011) Autism Speaks, the world,s ... largest genomic organization in the world and a global ... to create the world,s largest library of sequenced genomes ... Autism Speaks Autism Genetic Resource Exchange (AGRE), this collaboration ...
... world-best efforts to pluck out just the right stem cells ... sclerosis and a large number of rare, fatal children,s diseases. ... from the human brain to become oligodendrocytes the type ... that coats neurons and allows them to signal effectively ...
... the world will benefit from a new, pan-Canadian Terry ... the way in which ovarian cancer is diagnosed and ... are providing a total of $5-million in funding for ... The program will identify new biomarkers to predict and ...
... 13 (HealthDay News) -- The percentage of children with asthma ... has nearly doubled since the late 1990s, a new federal ... Medical Expenditure Panel Survey showed that the use of controller ... to 58 percent in 2007-2008, according to the latest ...
... written about health care disparities between Latinos and non-Latino whites, ... same disparities from the perspective of the patient, in terms ... But how do the physicians feel about ... face in treating Latino patients, compared with physicians whose patients ...
... sending too many patients by helicopter, an expensive choice that ... to travel between hospitals and time is of the essence, ... desirable than taking a ground ambulance, but a paper published ... this common assumption, revealing that the actual times to treatment ...
Cached Medicine News:Health News:Autism Speaks and BGI to complete whole genome sequencing on 10,000 with autism 2Health News:Precision with stem cells a step forward for treating MS, other diseases 2Health News:Precision with stem cells a step forward for treating MS, other diseases 3Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 2Health News:Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide 3Health News:Use of Asthma Controller Meds on the Rise Among U.S. Kids 2Health News:Physicians treating Latinos have high hurdles to jump, study shows 2Health News:Interfacility helicopter ambulance transport of neurosurgical patients 2
... GORE-TEX Stretch Vascular Grafts have ... demanding vascular procedures. Recognized for exceptional ... the endorsement of renowned surgeons worldwide. ... dilatation and the spread of infection, ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
... Vascular Graft, the newest vascular graft offering ... leader in vascular surgical products for more ... reducing kinking and compression problems that ... graft provides all of the benefits of ...
... Monitoring (IOM). Minimize risks during ... nervous system. Time-stamped event notation, data ... visual overview of the case using ... software allows simultaneous frequency analysis of ...
Medicine Products: